Research snapshot · Not reviewed

GHGuardant Health

Liquid biopsy, oncology screening

Open GH in Robinhood ↗

WATCH

Conviction●○○○○1 of 5

Research target—Snapshot target

Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed

Market cap22.27BSnapshot value

The thesis

Liquid biopsy pure-play: Guardant360/Guardant Reveal for oncology MRD and early detection. Recurring test-volume revenue model.

Catalysts

Colorectal cancer screening guideline inclusion (Shield blood test); MRD clinical adoption (Guardant Reveal); rising cancer burden driving testing volume.

What breaks it

Reimbursement risk (CMS coverage decisions); competitive pressure from Natera (Signatera) and Exact Sciences; binary regulatory outcomes on new test approvals.

Social sentiment

needs X/Reddit sentiment sweep

Snapshot · Not reviewed

Smart money

🟢 Lean-Bull · 13F 17+/8- · short↓0.16

Snapshot · Not reviewed